| Drug General Information |
| Drug ID |
D0Y2HH
|
| Former ID |
DCL000142
|
| Drug Name |
KC706
|
| Indication |
Inflammatory bowel disease; Rheumatoid arthritis; Cardiovascular disorders; Psoriasis [ICD9: 390-459, 555, 556, 696, 710-719, 714; ICD10:I00-I99, K50, K51, L40, M00-M25, M05-M06]
|
Discontinued in Phase 2 |
[1]
|
|---|
| Company |
Kemia
|
| Target and Pathway |
| Target(s) |
MAP kinase p38 |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Rap1 signaling pathway
|
|
FoxO signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Oocyte meiosis
|
|
Adrenergic signaling in cardiomyocytes
|
|
VEGF signaling pathway
|
|
Osteoclast differentiation
|
|
Signaling pathways regulating pluripotency of stem cells
|
|
Platelet activation
|
|
Toll-like receptor signaling pathway
|
|
NOD-like receptor signaling pathway
|
|
RIG-I-like receptor signaling pathway
|
|
T cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
TNF signaling pathway
|
|
Leukocyte transendothelial migration
|
|
Neurotrophin signaling pathway
|
|
Retrograde endocannabinoid signaling
|
|
Dopaminergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
GnRH signaling pathway
|
|
Progesterone-mediated oocyte maturation
|
|
Prolactin signaling pathway
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Epithelial cell signaling in Helicobacter pylori infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pertussis
|
|
Leishmaniasis
|
|
Chagas disease (American trypanosomiasis)
|
|
Toxoplasmosis
|
|
Tuberculosis
|
|
Hepatitis C
|
|
Influenza A
|
|
Epstein-Barr virus infection
|
|
Proteoglycans in cancer
|
|
NetPath Pathway
|
TCR Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
B cell activation
|
|
EGF receptor signaling pathway
|
|
FGF signaling pathway
|
|
Interferon-gamma signaling pathway
|
|
Oxidative stress response
|
|
Parkinson disease
|
|
TGF-beta signaling pathway
|
|
Ras Pathway
|
|
p53 pathway feedback loops 2
|
|
p38 MAPK pathway
|
|
Pathway Interaction Database
|
RhoA signaling pathway
|
|
Signaling mediated by p38-gamma and p38-delta
|
|
Reactome
|
NOD1/2 Signaling Pathway
|
|
p38MAPK events
|
|
Activation of PPARGC1A (PGC-1alpha) by phosphorylation
|
|
CDO in myogenesis
|
|
DSCAM interactions
|
|
VEGFA-VEGFR2 Pathway
|
|
WikiPathways
|
Toll-like receptor signaling pathway
|
|
Insulin Signaling
|
|
MAPK Cascade
|
|
MAPK Signaling Pathway
|
|
Nanoparticle-mediated activation of receptor signaling
|
|
Signal Transduction of S1P Receptor
|
|
Parkinsons Disease Pathway
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
NGF signalling via TRKA from the plasma membrane
|
|
Myogenesis
|
|
Integrin-mediated Cell Adhesion
|
|
DSCAM interactions
|
|
Regulation of toll-like receptor signaling pathway
|
| References |
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800023346) |
|---|
| REF 2 | KC706, an Oral p38 MAP Kinase Inhibitor, Increases HDL-C. Circulation. 2007;116:II_126. |
|---|
